Xeris Pharmaceuticals Inc. (XERS) Tops Q4 EPS by 4c, provides guidance

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q4 EPS of $0.06, $0.04 better than the analyst estimate of $0.02. Revenue for the quarter came in at $85.81 million versus the consensus estimate of $81.38 million.

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2026 revenue of $375-390 million, versus the consensus of $368 million.
Gross margin to improve modestly compared to 2025 reflecting favorable product mix.
R&D expense to increase by approximately $25 million compared to 2025 as the Company initiates its Phase 3 study for XP-8121.
SG&A expense to increase by approximately $45 million compared to 2025, driven primarily by investments in Recorlev.
Adjusted EBITDA1 to increase in total dollars compared to 2025.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance